RHOVAC APS
RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells. Overexpression of RhoC protein is a characteristic of most type of metastatic cancer cells. The cancer vaccine product RV001, already in clinical trial, recognises cells with high concentration of RhoC and stimulate the immune system to target them. RhoVac’s concept focuses on eliminating cancer cells having metastatic potential that escape treatment of the parent tumour via other methods. The company is based in Sweden and Denmark and is publicly traded in Swedish stock market. RhoVac is managed and advised by a senior team of executives with extensive expertise built upon years of experience.
RHOVAC APS
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
2008-01-01
Address:
Hørsholm, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.rhovac.com
Total Employee:
11+
Status:
Active
Contact:
+45 4083 2365
Email Addresses:
[email protected]
Total Funding:
2.5 M EUR
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Horizon 2020
Horizon 2020 investment in Grant - Rhovac ApS
Official Site Inspections
http://www.rhovac.com Semrush global rank: 5.91 M Semrush visits lastest month: 1.4 K
- Host name: splash.curanet.dk
- IP address: 212.237.249.16
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "Rhovac ApS"
CHOSA Oncology
CHOSA Oncology Presented at Økonomisk Ugebrev Investor Conference. CHOSA Oncology was presented by our CCO Claus Frisenberg at the Økonomisk Ugebrev Investor Conference on …See details»
Rhovac ApS - Crunchbase Company Profile & Funding
RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells. Overexpression of RhoC protein is a characteristic of most …See details»
RhoVac AB (under name change to Chosa Oncology AB) has …
About RhoVac AB (under name change to Chosa Oncology AB) Chosa is listed on the Spotlight Stock Market in Sweden and was formed after a reverse takover with RhoVac in January …See details»
RhoVac becomes Chosa Oncology after acquisition - BioStock
Deal to merge with RhoVac completed. As of Wednesday, the potential mentioned above is being pursued in a listed setting, with Lund-based RhoVac completing the deal to acquire Chosa …See details»
RhoVac 2025 Company Profile: Valuation, Investors, Acquisition
RhoVac was founded in 2007. Where is RhoVac headquartered? RhoVac is headquartered in Lund, Sweden. What is the size of RhoVac? RhoVac has 13 total employees. What industry is …See details»
RhoVac - Qualifyze
Founded in 2007, RhoVac® originated as a privately owned organization in Denmark. Subsequently, the initial strides were taken toward the development of the drug candidate, …See details»
Rhovac ApS - Craft
Rhovac ApS is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells. It offers medical therapy, radiotherapy, surgical instruments, …See details»
RhoVac - 2025 Company Profile, Funding & Competitors - Tracxn
Apr 27, 2025 RhoVac is a public company based in Copenhagen (Denmark), founded in 2007. It operates as a Developer of vaccines for the treatment of metastatic cancer. RhoVac has …See details»
RhoVac ApS - Drug pipelines, Patents, Clinical trials - Synapse
Explore RhoVac ApS with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, Disease Domain:Neoplasms, Technology Platform:Synthetic peptide ...See details»
Rhovac ApS - VentureRadar
Similar Companies: Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, …See details»
RhoVac AB changes name to CHOSA Oncology AB
On 11 January 2023, an Extraordinary General Meeting in RhoVac AB was held. The General Meeting resolved to approve the Board of Directors’ proposal to approve the acquisition of …See details»
RhoVac AB byter namn till CHOSA Oncology AB
Den 11 januari 2023 hölls en extra bolagsstämma i RhoVac AB. Stämman beslutade att godkänna styrelsens förslag om att godkänna förvärvet av CHOSA ApS, samt att ändra …See details»
Rhovac ApS | Company | Mindmaps
RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells. Investors. Horizon 2020 Estimated Revenue: $1M to $10M. …See details»
Rhovac ApS | VentureRadar
RhoVac® is a pharmaceutical company dedicated to immuno-oncology, signifying that the body’s own immune system is stimulated to identify and destroy cancer cells. ... Dansk Biotek …See details»
RhoVac’s co-founder Anders Ljungqvist has passed away
Dec 27, 2022 RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In …See details»
Rhovac ApS - Funding, Financials, Valuation & Investors
RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells. New. Resources. Advanced Search. ... How much funding has …See details»
RhoVac provides a status update and investigates a potentially ...
Jun 30, 2022 RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In …See details»
Rhovac ApS - Contacts, Employees, Board Members, Advisors
Organization. Rhovac ApS . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Rhovac ApS has 3 current employee profiles, including …See details»
RhoVac's events during May - August - CHOSA Oncology
RhoVac has launched a clinical phase IIb trial that will include at least 180 prostate cancer patients. The study is designed to show, with statistical significance, the effect of RV001 in …See details»
RhoVacs VD, Anders Månsson, har lämnat in sin avskedsansökan
RhoVac har nu passerat de tidiga stadierna av utveckling. Under 2019 påbörjades en patientrekrytering till en större klinisk fas IIb-studie som inkluderade drygt 180 patienter med …See details»